October 12, 2016 – This is a communication from Health Canada, issued in May 2016, concerning the danger of reactivation of hepatitis B virus (HBV) infection in patients treated with BCR-ABL tyrosine kinase inhibitors (TKIs) and geared towards healthcare professionals (medical …

BCR-ABL Tyrosine Kinase Inhibitors: Danger of HBV-Reactivation Read more »

October 05, 2016 – Here, we make available to our readers a Drug Safety Communication by the American Food & Drug Administration (FDA), where FDA warns about the risk of hepatitis B virus (HBV) reactivation in some patients treated with …

FDA warns about the risk of HBV reactivation in patients treated with DAA for HCV-infection Read more »